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Abstract  
Objectives: HIV has become a chronic condition associated with comorbidities.  We 
investigated cardiovascular (CV) risk and risk modification in a European HIV-Cohort. 
Methods: EuroSIDA patients (from 1/1/2000) for whom CV-risk could be calculated (D:A:D 
risk equation) were included in the analysis. Moderate to high risk was defined as 5-year CV 
risk >5% and risk modification as two measurements meeting the European AIDS Clinical 
Society guidelines. Factors associated with risk development and modifications were 
investigated using Poisson regression. Results: Of 8762 individuals, 32.1% were 
hypertensive, 45.0% had high cholesterol, 47.4% were current smokers, and 27.1% were 
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overweight. 1504 (17.2%) had a 5-year CV-risk of > 5%. Of 7258 individuals with a 5-year 
risk <5%, 1905 (26.2%) developed CV-risk > 5%, (6.53/100 person-years). These patients 
were more likely to be older, men, living in East Europe, with traditional CV-risk factors. 
Men who have sex with men, with longer exposure to antiretroviral therapy, low CD4 nadir, 
higher current CD4, and prior AIDs events were more likely to develop CV-risk. Those on 
antihypertensive treatment and living in central Europe were less likely to develop CV-risk. 
Of those clinically indicated for risk modification, 1205/2077(58.0%) successfully modified 
BP; 1283/3919(32.8%) stopped smoking; 277/1394(19.9%) modified cholesterol and 
543/2163(25.1%) reduced their BMI. There was variation in modification of individual risk 
factors, by gender, age, HIV related factors, and region of follow-up. Risk modification for 
BP and smoking improved over time (p<0.001). Conclusion:  CV-risk was common. More 
than half modified their CV risk and this improved over time.  
Keywords: HIV, cardiovascular risk, cohort, antiretoviral therapy, europe 
 
Background  
CV disease is the leading cause of death in Europe, accounting for nearly half of all-cause 
mortality
1
. Prolonged survival due to successful antiretroviral management of people living 
with HIV (PLHIV) has resulted in a cohort at increased risk of comorbidities and chronic 
diseases related to aging such as cardiovascular disease
2-6
. Studies suggest that there is a 
greater prevalence of some modifiable cardiovascular (CV) risk factors in PLHIV and that 
HIV and/or HIV treatment may be an independent risk factor for CV disease
7-9
. In order to 
sustain the successes of combination antiretroviral therapy (cART) in reducing mortality and 
morbidity
2
 in PLHIV and accessing care in Europe we need to ensure that there is an equally 
vigorous approach to the management of the comorbidities associated with HIV and aging, 
and in particular CV disease. 
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Patterns of CV risk vary across geographical settings and populations, partly due to genetic 
factors and partly due to lifestyle and environmental factors
1
. Successful management of CV 
diseases requires a stepped care approach: primary prevention, identifying risk factors, non-
pharmacological management of modifiable risk factors, pharmacological management of 
risk factors and finally specialist care
10-12
.  Although there has been growing awareness of the 
clustering of health related risk and consequently long-term conditions, integrated 
management frequently fails. For example, a review found that even in well- functioning 
health systems less than half of people with diabetes underwent screening and treatment of 
modifiable CV risk factors
13;14
.  
PLHIV are followed up regularly, however although this provides the opportunity to manage 
co-morbidities, we have limited data on stepped care for CV disease: In particular of those 
identified to have a modifiable risk factor, what proportion achieves modification of their risk 
factor and what are the predictors of success?  
The aim of this paper is to describe the patterns of modifiable CV risk and explore predictors 
of successful medical management of modifiable risk in HIV positive individuals accessing 
HIV care within the EuroSIDA cohort.   
Methods  
Population  
The EuroSIDA study is a prospective observational cohort of 18,791 HIV-1 positive adult 
patients in 108 clinics across 34 European countries, Israel and Argentina.  This study has 
been described previously
15
. In brief, patients were enrolled from nine cohorts from May 
1994 onwards.  Information is collected onto standardised data collection forms every 6 
months, including all CD4 cell counts and viral loads measured since the last follow-up and 
starting and stopping dates for all cART. For the purposes of this analysis we include all the 
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individuals enrolled in EuroSIDA after 1/1/2000 for whom at least two measurements of 
predicted CV risk could be calculated, using two different sets of time-updated variables. The 
baseline date was considered the date when the risk equation could first be calculated.  
 
Measurement:  
Time-updated cardiovascular variables contributing to the construction of the predicted risk 
estimates were carried forward for a maximum of 12 months. Development of moderate/high 
CV risk was defined as a predicted 5 year CV risk of over 5% using both D.A.D. and 
Framingham equations
16;17
. We used a conservative estimate of a predicted 5 year CV risk of 
5%- equivalent to a 10 year CV risk of 10%, in order to capture individuals with both 
moderate and high CV risk.  Modifiable risks; hypertension, smoking, high serum 
cholesterol, diabetes and being overweight, were defined according to European AIDS 
Clinical society guidelines (Table 1) and successful CV risk modification was defined as two 
consecutive measurements meeting the same guidelines.  Weight loss from a BMI of over 25 
to one that is less than 25 was used as a surrogate marker of successful lifestyle interventions 
(exercise and diet). 
 
Statistical methods:  
Baseline associations between risk factors and predicted CV risk were evaluated using 
logistic regression.  
 
Rates of risk development and risk modification were calculated by dividing the total person 
years of follow-up (PYFU) with the number of events. Person-time with incomplete covariate 
data were excluded from the calculation of rates and rate ratios.  Individuals were followed 
until they experienced the outcome of interest for the first time If the outcome of interest did 
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not occur, individuals were censored 6 months after their last available modifiable risk factor 
measurement (which equates to their last available risk estimate) or 31/12/2014 whichever 
occurred first. For the analysis of risk modification, individuals were censored 6 months after 
their last available measurement of the relevant modifiable risk factor or at 31/12/2014, 
whichever occurred first. Factors associated with CV risk development and risk modification 
were investigated using Poisson regression. 
 
All models were adjusted for socio-demographic variables (gender, ethnicity, risk group, 
region), calendar year, HIV related variables (CD4-cell count, CD4 nadir, prior AIDS 
diagnosis, prior AIDS or non-AIDS event, cumulative cART exposure, viral load 
suppression,) hepatitis B and C; and CV-related variables (hypertension and treatment, 
hyperlipidaemia and treatment, smoking status, BMI, diabetes and Family history of CV 
disease). All analyses were conducted using SAS 9.3 (Statistical Analysis Software, Cary 
NC, USA). 
 
Results  
 
Prevalence, incidence and pattern of CV risk 
A total of 8762 individuals were included in the analysis. The baseline characteristics can be 
seen in Table 2. The majority of individuals were male (76.0%), white (87.1%) and had 
acquired their infection through sex with another man (45.2%).  
 
The prevalence of traditional CV risk factors as defined in table 1 was high; 32.0% of 
individuals were hypertensive, 27.1% overweight, 45.0% had high cholesterol levels, 5% had 
diabetes mellitus (DM) and 47.4% were current smokers. At baseline 1504 (17.2%) of 
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individuals had a moderate to high (5% five year) CV risk according to the D.A.D risk 
assessment and 1729 (19.7%) according to Framingham’s.  
After adjustment (figure 1), having a high CV risk at baseline was associated with being male 
and older age. CD4 Nadir of less that 200 cells/µL, longer duration of cART, current CD4 
count of greater than 200 cells/µL and earlier year of entry into the cohort, were also 
associated with moderate/high CV risk.  
Among the 7258 individuals who had a low predicted baseline risk, 1905 (26.2%) went on to 
develop a moderate/high CV risk, with an overall incidence rate of 6.83 95% CI (6.53-7.34) 
/100 PYFU. Results from this analysis can be seen in figure 2.  Individuals who developed 
moderate to high CV risk were more likely to be, older men, with a family history of CV 
disease, living in East Europe, with traditional modifiable CV risk factors (smoking, 
hypertension, high cholesterol, overweight and diabetes). Men who had sex with men, and 
those with a longer cumulative exposure to cART, with a CD4 nadir of less than 200 
cells/µL, current CD4 count of greater than 500 cells/µL and prior AIDS were more likely to 
develop moderate/high CV risk; whilst there was no relationship between HIV viral load 
being controlled by cART and the development of CV risk. Those on antihypertensive 
treatment and living in central Europe were less likely to develop CV risk.  
Risk Modification 
1205 of 2077 (58.0%) individuals indicated for BP treatment successfully modified their BP, 
1283 of 3919 (32.8%) smokers stopped smoking, 277 of 1394 (19.9%) individuals indicated 
for lipid lowering treatment lowered their cholesterol levels and 543 of 2163 
(25.1%) overweight individuals lowered their BMI to below 25. 
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Blood pressure: In a multivariable Poisson model (table 3a), individuals less likely to 
modify their blood pressure (BP) were male, older, heterosexual, overweight, with high 
cholesterol, and diabetes.  Those with a family history of CVD and who had a prior CV event 
were more likely to modify their BP.  There was some evidence of regional differences, with 
individuals from northern Europe less likely to modify their blood pressure as compared to 
individuals from southern Europe. Those with higher base line BP, those on anti-hypertensive 
medication and those with CD4 counts of greater than 200 cells/µL were less likely to control 
BP. There was no association between BP control and HIV viral load.   BP control improved 
over time.  
Smoking:  Table 3b shows that after adjustment there was good evidence that the rate of 
smoking cessation differed according to mode of infection and region, with injecting drug 
users and individuals from eastern Europe less likely to stop smoking. Those with a CD4 
nadir of less than 200 cells/µL and detectable viral loads were less likely to stop smoking. 
Those with a prior CV event were more likely to stop smoking. Rates of smoking cessation 
improved over time. 
Cholesterol: After adjustment (Table 3c): Those with higher CD4 counts and undetectable 
viral load were less likely to reduce their cholesterol.  People with higher baseline cholesterol 
and diabetes were less likely to successfully reduce their cholesterol. Those with a prior CVD 
event were more likely to control their cholesterol. There was no evidence for gender or age 
related differences in modification of cholesterol levels and there was no change in 
cholesterol modification over time. 
Time Trends: We found evidence that modification of blood pressure and smoking increased 
over time: After adjustment the rate of blood pressure modification increased by 6% per 
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calendar year (aIRR=1.06, 1.03-1.09, p<0.0001) and the rate of smoking cessation by 5% per 
year (aIRR=1.05, 1.02-1.07, p<0.0001).  
 
Discussion  
This study has demonstrated that the prevalence and incidence of CV risk in people accessing 
HIV care is very high and only a modest proportion are able to modify any of their CV risk 
factors. However, risk modification seems to be improving over time.   This needs to be 
interpreted in the context of a relatively robust HIV cascade of care within the same clinical 
settings, with more than 80% virologically suppressed on cART and despite compelling 
evidence of the effectiveness of CV risk modification in reducing CV morbidity and 
mortality.  Furthermore, the marked demographic and geographic heterogeneity in CV risk 
modification has profound implications on equity of care across Europe.  
In keeping with other studies the prevalence of CV risk was high
7-9
 and heterogeneous across 
demographics and geography
1
. However, the pattern of modifiable CV risk in this cohort 
varies considerably from general population estimates.  For example, in this cohort the 
prevalence of smoking and high cholesterol is much higher than the general population, 
whilst the prevalence of hypertension and obesity is comparable and possibly even lower than 
the background prevalence
18
. Specifically, in Europe approximately one in three people 
smoke, compared with one in two in this European cohort of PLHIV. Similarly in the country 
with the highest prevalence of hypercholesterolemia- Iceland, the general population 
prevalence is 29%, and the rest of Europe closer to one in five, suggesting that high 
cholesterol in this cohort was close to double the background prevalence
18
. These differences 
compared with general population prevalence may partly be explained by the characteristics 
of the EuroSIDA cohort; however, other HIV cohorts have also found similar high prevalence 
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of smoking and high cholesterol. Prevalence of hypertension and obesity of one in three is 
lower than that recorded in the background populations particularly of North and Western 
Europe
18
. The heterogeneous geographical distribution of modifiable risk factors, however, 
mirrors that of the background populations
18
.  
The prevalence and incidence of CV risk was high with 1 in 5 having moderate/high CV risk 
at baseline and 7% per annum developing moderate to high CV risk. This potentially has 
huge resource implications for European countries. The WHO Europe region is estimated to 
have 2.2 million people living with HIV
19
 of which extrapolating from this study over 
400,000 potentially have moderate/high CV risk, with another 120,000 developing 
moderate/high CV risk per annum and would require primary CV disease prevention in 
addition to their ongoing HIV care
19
.  
On a more positive note, being on antihypertensive treatment was associated with a lower 
probability of developing CV risk. This mirrors the findings from general population studies. 
Europe wide data has suggested that whilst there have been guideline driven increases in the 
prescription of drugs for primary and secondary prevention of CV disease, there remains 
marked geographic variation in prescription practices, particularly for vulnerable groups such 
as injection drug users, which is also reflected in the geographic variation in risk modification 
that we have seen
18
.  Whilst earlier diagnosis and more aggressive approaches to CV risk, 
including smoking cessation and other lifestyle interventions
20
, may reduce longer term 
morbidity and mortality this has resource implications that health systems squeezed by 
austerity may not be able to invest in, potentially exacerbating existing inequalities in quality 
of care across people living with HIV and accessing care in Europe. 
More than half modified their BP. The health survey of England suggested that only 1/3 
modified their BP whilst a review of management of diabetes in Europe found the number 
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closer to one in four, albeit of the more stringent target of 130/80
21
.  However, pilot studies in 
primary care settings in the UK found that by setting clinical targets, 62% of patients reached 
the target of 140/90 or less over six months of follow-up, suggesting that whilst HIV 
clinicians in Europe are doing well, they could do better
22
. The improvement in smoking and 
BP control over time mirrors the improvement in BP control and smoking cessation in the 
general population and may also reflect the emphasis and guidance around CV risk 
management in HIV that has emerged over time. The gender, age and geographical variation 
in management of BP and other risk, suggests that there are biological, social, cultural and 
health service related factors that need further investigation.  For example to what degree 
does the poor control in older age reflect the effect of poly-pharmacy and age related 
metabolic changes on pharmacodynamics and side effects, resulting in poor adherence or 
variable drug levels in older populations? Alternatively, is this heterogeneity a reflection of 
the models of care and in particular the varying expertise and experience of managing CV 
risk in primary care settings compared to specialist HIV and/or infectious disease units?  For 
example, it is notable that those with a history of CVD, i.e. those who are eligible for 
secondary prevention of CVD were two times more likely to modify their lipids, 50% more 
likely to stop smoking and 20% more likely to reduce their blood pressure, suggesting room 
to improve primary prevention.  
One aspect that we are unable to directly comment on from this study is the relationship 
between adherence to cART and successful modification of CV risk factors. On the one hand 
those who had undetectable HIV viral loads were more likely to stop smoking, perhaps an 
indication of engagement in care. On the other hand those who successfully managed their 
HIV, with undetectable viral load and higher CD4 counts, were less able to reduce their 
cholesterol to recommended levels, perhaps reflecting the effect of some antiretroviral 
therapy on cholesterol. Unfortunately, we are unable to comment on whether clinicians 
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switched cART to manage lipids. Overall HIV related factors had less impact on successful 
reduction in cholesterol than being on a statins.  
The limitation of this study should be noted.  Although EuroSIDA is one of the larger 
observational cohorts, CV clinical events were uncommon and therefore we did not have the 
power to look at the effect of risk modification on CV clinical outcomes. The findings are 
therefore restricted to CV risk modification and we are unable to comment as to whether CV 
risk modification is as effective in people living with HIV as has been observed in general 
population cohorts, further combinations of cohorts would be required to answer this 
question.  Secondly, we have presented the D.A.D risk prediction tool, which is both a 
conservative estimate of risk (5%, 5 year comparable with a 10%, 10 year Framingham risk) 
and CV risk tool, which is not in common clinical use. However, in this cohort both medium 
and high D.A.D CV risk measurements predicted substantial CV events that were higher than 
those predicted by Framingham’s (unpublished data).  We repeated our analyses using the 
Framingham equation and the findings were comparable. Thirdly we were concerned that 
there would be a risk of channeling bias, with those with higher CV risk being more likely to 
have a second CV risk measure, however, in fact the opposite was true and they were less 
likely to have a second CV risk measurement (unpublished data available from the authors).  
Third, given the numbers of those who had diabetes mellitus (DM) we were unable to look at 
the risk modification of this important risk factor for cardiovascular disease. However, we 
note those with DM were 76% less likely to modify their BP, which given the risk of cerebral 
vascular events and chronic renal failure in this group suggests a need to focus on 
management of BP in PLHIV and DM. Finally, the patients in the EuroSIDA cohort and in 
these analyses represent a group of patients who are engaged in care, with good HIV related 
outcomes, consequently the actual cascade of CV care is likely to be worse than what is 
reported in this study.  
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
In conclusion, to sustain the morbidity and mortality benefits of antiretroviral therapy we 
need to tackle the intersecting epidemic of HIV and other comorbidities, including CV risk. 
Whilst this study suggests that we are improving in recognition and treatment of CV risk, 
particularly BP and smoking, we need to do much more, particularly for older people, men 
and those with DM.  We need to better understand the reasons for the geographical variation, 
tackle inequities in access to care, and advocate for the resources needed to manage CV risk. 
It is important to develop innovative models of patient centered integrated HIV and CV 
disease care and to evaluate them with both HIV and CV end points in mind.  
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Table 1: Definitions of modifiable CV risk factors and risk modification outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Included as an indication of positive lifestyle changes and not based on the EACS guidelines.
Modifiable CV risk factors (for description 
of study population) 
Clinical indication for risk modification 
according to EACS guidelines  
Successful risk modification 
(Two consecutive measures within 12 months of each 
other)  
Hypertension  
(systolic blood pressure (BP) >140 mm Hg, 
diastolic BP >90 mm Hg or on 
antihypertensive treatment) 
systolic BP >140 or diastolic BP >90 mm Hg Systolic BP <140 (130 if diabetic) and diastolic BP <90 
(<80 if diabetic) mm Hg 
High cholesterol  
(total cholesterol>6 mmol/l, cholesterol:hdl 
cholesterol ratio >5 or receiving statins) 
Predicted 10 year Framingham CV risk of over 
20%, diabetic, or established CV disease  
Lowering total cholesterol to less than 4 mmol/l 
Current smoker   Current smoker  Stopped smoking  
Overweighta 
(Body Mass Index (BMI) over 25 kg/m2)  
 Lowering BMI to less than 25 kg/m2 (and more than 18 
kg/m2) 
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1. MSM=Men Who Have Sex With Men. 
2. PWID=Person Who Injects Drugs.  
3. Data on 309 individuals from Argentina are not presented here to preserve the anonymity of EuroSIDA countries. 
4. 11 individuals had missing CD4 data at baseline.  
5. 11 individuals had missing CD4 nadir data at baseline.  
6. 65 individuals had missing RNA values at baseline
Table 2:  Characteristics of the Study Population According to Baseline CV Risk 
   Total High Risk (DAD)  High Risk (Framingham) 
     N N (%) N (%) 
Total    8762    1504 (17.2)    1729 (19.7) 
Demographics    
Gender Female 2078 88 (4.2) 116 (5.6) 
  Male 6684 1416 (21.2) 1613 (24.1) 
Age Median, IQR 42 (35.7 - 49.9) 56 (50.5 - 62.7) 55 (49.6 - 61.5) 
Year of Entry (MM/YY) Median, IQR  01/06 (05/02-12/08)    01/06 (05/02-08/09)    11/05 (01/02-12/08) 
Ethnicity White 7639 1359 (17.8) 1568 (20.5) 
  Non-white 1123 145 (12.9) 161 (14.3) 
Mode of Infection MSM
1
 3957 839 (21.2) 968 (24.5) 
  PWID
2
 1486 141 (9.5) 158 (10.6) 
  Heterosexual 2705 383 (14.2) 443 (16.4) 
  Other/Unknow
n 
614 141 (23.0) 160 (26.1) 
European Region
3
 South 2179 310 (14.2) 376 (17.3) 
  Central 2543 543 (21.4) 607 (23.9) 
  North 1909 460 (24.1) 526 (27.6) 
  East 1822 173 (9.5) 185 (10.2) 
HIV-related variables       
CD4 group
4
 <200 889 117 (13.2) 152 (17.1) 
  200-350 1892 362 (19.1) 383 (20.2) 
  350-500 2225 370 (16.6) 441 (19.8) 
  >500 3745 654 (17.5) 752 (20.1) 
CD4 nadir
5
 <200 5039 1016 (20.2) 1130 (22.4) 
  >200 3712 487 (13.1) 598 (16.1) 
HIV RNA (cp/ml)
6
 <400  6421 1237 (19.3) 1371 (21.4) 
  >400  2276 263 (11.6) 352 (15.5) 
Prior AIDS event  2477 551 (22.2) 596 (24.1) 
Prior non-AIDS event (not CV)  457 122 (26.7) 118 (25.8) 
Cumulative cART exposure < 1 year 1850 130 (7.0) 968 (24.5) 
  1-3 years 1866 198 (10.6) 158 (10.6) 
  3-6 years 2643 494 (18.7) 443 (16.4) 
  >6 years 2403 682 (28.4) 160 (26.1) 
Hepatitis B  501 84 (16.8) 95 (19.0) 
Hepatitis C  1488 140 (9.4) 155 (10.4) 
Cardio Vascular Disease (CVD) -related variables       
Hypertensive  2811 869 (30.9) 1131 (40.2) 
On antihypertensives  864 378 (43.8) 432 (50.0) 
High Cholesterol  3950 1058 (26.8) 1252 (31.7) 
On lipid lowering drugs  477 197 (41.3) 218 (45.7) 
Current Smoker  4152 925 (22.3) 991 (23.9) 
Overweight  2371 493 (20.8) 620 (26.1) 
Diabetic  487 306 (62.8) 335 (68.8) 
Family History of CVD  793 237 (29.9) 171 (21.6) 
Prior CVD event  261 141 (54.0) 140 (53.6) 
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Table 3a. Incidence Rates and Rate Ratios for modifying blood pressure 
    N PYFU Rate (95%CI) per 100 PYFU Univariable Multivariable 
         RR (95%CI) P-value RR (95%CI) P-value 
Total   1204 7668 15.70 (14.84 - 16.61)         
Gender Female 222.0 1055 21.04 (18.45 - 24.00) 1.00   1.00   
  Male 982.0 6613 14.85 (13.95 - 15.81) 0.71 (0.61 - 0.82) <.001 0.68 (0.57 - 0.81) <.001 
Age at baseline Per 10 years       0.75 (0.71 - 0.80) <.001 0.90 (0.85 - 0.96) 0.002 
Year 2000-2001 47.0 431.2 10.90 (8.19 - 14.51) 1.00   1.00   
  2002-2003 164.0 875.9 18.72 (16.07 - 21.82) 1.72 (1.24 - 2.38) 0.001 1.87 (1.35 - 2.59) <.001 
  2004-2005 181.0 1017 17.80 (15.39 - 20.59) 1.63 (1.18 - 2.25) 0.003 2.02 (1.45 - 2.82) <.001 
  2006-2007 190.0 1153 16.49 (14.30 - 19.00) 1.51 (1.10 - 2.08) 0.011 2.09 (1.49 - 2.91) <.001 
  2008-2009 184.0 1293 14.23 (12.32 - 16.45) 1.31 (0.95 - 1.80) 0.103 1.91 (1.36 - 2.68) <.001 
  2010-2011 189.0 1214 15.57 (13.50 - 17.95) 1.43 (1.04 - 1.97) 0.029 2.22 (1.57 - 3.13) <.001 
  2012-2014 249.0 1684 14.78 (13.06 - 16.74) 1.36 (0.99 - 1.85) 0.055 2.02 (1.44 - 2.83) <.001 
Ethnicity White 1083 6808 15.91 (14.99 - 16.88) 1.00   1.00   
  Non-white 121.0 860.1 14.07 (11.77 - 16.81) 0.88 (0.73 - 1.07) 0.200 0.94 (0.76 - 1.16) 0.563 
Mode of Infection MSM 572.0 3813 15.00 (13.82 - 16.28) 1.00   1.00   
  PWID 194.0 775.3 25.02 (21.74 - 28.80) 1.67 (1.42 - 1.96) <.001 1.05 (0.83 - 1.33) 0.694 
  Heterosexual 339.0 2427 13.97 (12.55 - 15.53) 0.93 (0.81 - 1.06) 0.297 0.81 (0.69 - 0.95) 0.010 
  Other/Unknown 99.0 651.7 15.19 (12.48 - 18.50) 1.01 (0.82 - 1.25) 0.907 0.94 (0.76 - 1.18) 0.615 
Region South 292.0 1653 17.66 (15.75 - 19.81) 1.00   1.00   
  Central 380.0 2354 16.14 (14.60 - 17.85) 0.91 (0.78 - 1.06) 0.248 0.94 (0.80 - 1.11) 0.463 
  North 261.0 2326 11.22 (9.94 - 12.67) 0.64 (0.54 - 0.75) <.001 0.66 (0.55 - 0.79) <.001 
  East 241.0 1178 20.45 (18.03 - 23.20) 1.16 (0.98 - 1.37) 0.092 0.95 (0.79 - 1.14) 0.553 
HIV-related variables                   
CD4 group <200 83.0 420.0 19.76 (15.94 - 24.51) 1.00   1.00   
  200-350 200.0 1261 15.85 (13.80 - 18.21) 0.80 (0.62 - 1.04) 0.092 0.75 (0.58 - 0.98) 0.035 
  350-500 285.0 1877 15.19 (13.52 - 17.06) 0.77 (0.60 - 0.98) 0.035 0.72 (0.56 - 0.93) 0.012 
  >500 636.0 4108 15.48 (14.32 - 16.73) 0.78 (0.62 - 0.98) 0.036 0.74 (0.57 - 0.94) 0.016 
CD4 nadir <200 686.0 4599 14.92 (13.84 - 16.08) 1.00   1.00   
  >200 516.0 3061 16.86 (15.47 - 18.38) 1.13 (1.01 - 1.27) 0.036 1.11 (0.97 - 1.27) 0.137 
HIV RNA (cp/ml) <400 (suppressed) 1010 6636 15.22 (14.31 - 16.19) 1.00   1.00   
  >400  193.0 1024 18.85 (16.37 - 21.71) 1.24 (1.06 - 1.44) 0.006 1.06 (0.89 - 1.26) 0.536 
Prior AIDS event No 869.0 5410 16.06 (15.03 - 17.17) 1.00   1.00   
  Yes 335.0 2258 14.84 (13.33 - 16.51) 0.92 (0.81 - 1.05) 0.217 0.96 (0.84 - 1.10) 0.573 
Prior non-AIDS event (not 
CV) 
No 1140 7317 15.58 (14.70 - 16.51) 1.00   1.00   
  Yes 64.0 350.8 18.24 (14.28 - 23.31) 1.17 (0.91 - 1.51) 0.220 1.18 (0.91 - 1.53) 0.220 
Cumulative cART exposure <1 year 96.0 524.5 18.30 (14.98 - 22.36) 1.00   1.00   
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
  1-3 years 150.0 783.1 19.16 (16.32 - 22.48) 1.05 (0.81 - 1.35) 0.728 1.15 (0.88 - 1.51) 0.316 
  3-6 years 325.0 1832 17.74 (15.92 - 19.78) 0.97 (0.77 - 1.22) 0.789 1.24 (0.97 - 1.60) 0.087 
  >6 years 633.0 4528 13.98 (12.93 - 15.11) 0.76 (0.62 - 0.95) 0.014 1.10 (0.86 - 1.41) 0.444 
Hepatitis B No 1063 6868 15.48 (14.58 - 16.44) 1.00   1.00   
  Yes 82.0 416.9 19.67 (15.84 - 24.42) 1.27 (1.02 - 1.59) 0.037 1.15 (0.91 - 1.45) 0.233 
  Unknown 59.0 383.0 15.40 (11.94 - 19.88) 1.00 (0.77 - 1.29) 0.972 0.86 (0.65 - 1.13) 0.280 
Hepatitis C No 799.0 5492 14.55 (13.57 - 15.59) 1.00   1.00   
  Yes 207.0 902.2 22.94 (20.02 - 26.29) 1.58 (1.35 - 1.84) <.001 1.10 (0.88 - 1.37) 0.415 
  Unknown 198.0 1274 15.55 (13.52 - 17.87) 1.07 (0.91 - 1.25) 0.404 0.97 (0.82 - 1.15) 0.740 
CVD-related variables (all baseline)              
Blood Pressure 
 
             
  Per 10       0.77 (0.74 - 0.81) <.001 0.82 (0.78 - 0.86) <.001 
On antihypertensives No 1035 6115 16.92 (15.92 - 17.99) 1.00   1.00   
  Yes 169.0 1552 10.89 (9.36 - 12.66) 0.64 (0.55 - 0.76) <.001 0.84 (0.70 - 0.99) 0.043 
High Cholesterol    No 583.0 3142 18.56 (17.11 - 20.13) 1.00   1.00   
  Yes 621.0 4526 13.72 (12.68 - 14.84) 0.74 (0.66 - 0.83) <.001 0.86 (0.76 - 0.98) 0.018 
On lipid lowering drugs No 1133 7084 15.99 (15.09 - 16.95) 1.00   1.00   
  Yes 71.0 583.2 12.17 (9.65 - 15.36) 0.76 (0.60 - 0.97) 0.026 0.98 (0.76 - 1.26) 0.884 
Current Smoker No 625.0 4419 14.14 (13.08 - 15.30) 1.00   1.00   
  Yes 559.0 3098 18.04 (16.61 - 19.60) 1.28 (1.14 - 1.43) <.001 1.03 (0.91 - 1.17) 0.592 
  Ex 20.0 150.8 13.26 (8.55 - 20.55) 0.94 (0.60 - 1.46) 0.776 0.82 (0.52 - 1.30) 0.405 
Overweight No 806.0 4328 18.62 (17.38 - 19.95) 1.00   1.00   
  Yes 398.0 3340 11.92 (10.80 - 13.15) 0.64 (0.57 - 0.72) <.001 0.76 (0.67 - 0.86) <.001 
Diabetic No 1149 6302 18.23 (17.21 - 19.32) 1.00   1.00   
  Yes 55.0 1366 4.03 (3.09 - 5.24) 0.22 (0.17 - 0.29) <.001 0.24 (0.18 - 0.31) <.001 
Family History of CVD No 1060 6966 15.22 (14.33 - 16.16) 1.00   1.00   
  Yes 144.0 701.3 20.53 (17.44 - 24.18) 1.35 (1.13 - 1.61) <.001 1.23 (1.03 - 1.47) 0.021 
Prior CVD event No 1119 7064 15.84 (14.94 - 16.80) 1.00   1.00   
  Yes 85.0 603.5 14.08 (11.39 - 17.42) 0.89 (0.71 - 1.11) 0.296 1.60 (1.27 - 2.02) <.001 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Table 3b. Incidence Rates and Rate Ratios for stopping smoking 
    N PYFU Rate (95%CI) per 100 PYFU Univariable Multivariable 
         RR (95%CI) P-value RR (95%CI) P-value 
Total   1283 20850 6.15 (5.83 - 6.50)         
Gender Female 264.0 4440 5.95 (5.27 - 6.71)         
  Male 1019 16410 6.21 (5.84 - 6.60) 1.04 (0.91 - 1.20) 0.530 0.93 (0.80 - 1.10) 0.407 
Age at baseline Per 10 years       1.12 (1.06 - 1.19) <.001 1.02 (0.95 - 1.09) 0.631 
Year 2000-2001 84.0 897.6 9.36 (7.56 - 11.59) 2.46 (1.82 - 3.34) <.001 2.46 (1.81 - 3.35) <.001 
  2002-2003 81.0 2133 3.80 (3.05 - 4.72)         
  2004-2005 129.0 2966 4.35 (3.66 - 5.17) 1.15 (0.87 - 1.51) 0.338 1.10 (0.83 - 1.45) 0.526 
  2006-2007 195.0 3217 6.06 (5.27 - 6.97) 1.60 (1.23 - 2.07) <.001 1.50 (1.15 - 1.96) 0.003 
  2008-2009 248.0 3353 7.40 (6.53 - 8.38) 1.95 (1.52 - 2.50) <.001 1.79 (1.38 - 2.33) <.001 
  2010-2011 221.0 3341 6.62 (5.80 - 7.55) 1.74 (1.35 - 2.25) <.001 1.60 (1.23 - 2.09) <.001 
  2012-2014 325.0 4943 6.58 (5.90 - 7.33) 1.73 (1.36 - 2.21) <.001 1.60 (1.23 - 2.07) <.001 
Ethnicity White 1182 19253 6.14 (5.80 - 6.50)         
  Non-white 101.0 1597 6.33 (5.20 - 7.69) 1.03 (0.84 - 1.26) 0.774 0.97 (0.78 - 1.21) 0.814 
Mode of Infection MSM 583.0 8709 6.69 (6.17 - 7.26)         
  PWID 286.0 6045 4.73 (4.21 - 5.31) 0.71 (0.61 - 0.81) <.001 0.74 (0.60 - 0.91) 0.005 
  Heterosexual 348.0 5055 6.88 (6.20 - 7.65) 1.03 (0.90 - 1.17) 0.680 1.00 (0.85 - 1.17) 0.999 
  Other/Unknown 66.0 1041 6.34 (4.98 - 8.07) 0.95 (0.73 - 1.22) 0.678 0.99 (0.76 - 1.28) 0.921 
European Region South 370.0 5953 6.22 (5.61 - 6.88)         
  Central 327.0 5162 6.33 (5.68 - 7.06) 1.02 (0.88 - 1.18) 0.802 0.98 (0.84 - 1.15) 0.827 
  North 310.0 4218 7.35 (6.58 - 8.21) 1.18 (1.02 - 1.38) 0.030 1.12 (0.95 - 1.31) 0.167 
  East 226.0 5056 4.47 (3.92 - 5.09) 0.72 (0.61 - 0.85) <.001 0.75 (0.63 - 0.89) <.001 
HIV-related variables              
CD4 group <200 90.0 1466 6.14 (4.99 - 7.55)         
  200-350 193.0 3255 5.93 (5.15 - 6.83) 0.97 (0.75 - 1.24) 0.787 0.89 (0.69 - 1.15) 0.363 
  350-500 287.0 4501 6.38 (5.68 - 7.16) 1.04 (0.82 - 1.32) 0.752 0.90 (0.70 - 1.15) 0.384 
  >500 713.0 11627 6.13 (5.70 - 6.60) 1.00 (0.80 - 1.24) 0.994 0.76 (0.60 - 0.97) 0.025 
CD4 nadir <200 711.0 12220 5.82 (5.41 - 6.26)         
  >200 571.0 8615 6.63 (6.11 - 7.19) 1.14 (1.02 - 1.27) 0.020 1.27 (1.12 - 1.45) <.001 
HIV RNA (cp/ml) <400 (suppressed) 1102 17248 6.39 (6.02 - 6.78)         
  >400  178.0 3539 5.03 (4.34 - 5.83) 0.79 (0.67 - 0.92) 0.003 0.81 (0.68 - 0.97) 0.022 
Prior AIDS event No 910.0 15073 6.04 (5.66 - 6.44)         
  Yes 373.0 5778 6.46 (5.83 - 7.15) 1.07 (0.95 - 1.21) 0.276 1.10 (0.97 - 1.26) 0.135 
Prior non-AIDS event (not CV) No 1226 19804 6.19 (5.85 - 6.55)         
  Yes 57.0 1046 5.45 (4.20 - 7.07) 0.88 (0.68 - 1.15) 0.347 0.85 (0.65 - 1.11) 0.228 
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 Cumulative cART exposure <1 year 83.0 1617 5.13 (4.14 - 6.37)         
  1-3 years 132.0 2221 5.94 (5.01 - 7.05) 1.16 (0.88 - 1.52) 0.295 1.13 (0.85 - 1.51) 0.412 
  3-6 years 283.0 5101 5.55 (4.94 - 6.23) 1.08 (0.85 - 1.38) 0.533 1.11 (0.85 - 1.45) 0.433 
  >6 years 785.0 11912 6.59 (6.15 - 7.07) 1.28 (1.02 - 1.61) 0.030 1.24 (0.96 - 1.61) 0.099 
Hepatitis B No 1126 18123 6.21 (5.86 - 6.59)         
  Yes 91.0 1592 5.72 (4.66 - 7.02) 0.92 (0.74 - 1.14) 0.445 0.93 (0.75 - 1.15) 0.498 
  Unknown 66.0 1135 5.81 (4.57 - 7.40) 0.94 (0.73 - 1.20) 0.599 1.01 (0.79 - 1.31) 0.916 
Hepatitis C No 777.0 11466 6.78 (6.32 - 7.27)         
  Yes 317.0 6256 5.07 (4.54 - 5.66) 0.75 (0.66 - 0.85) <.001 1.01 (0.83 - 1.22) 0.957 
  Unknown 189.0 3128 6.04 (5.24 - 6.97) 0.89 (0.76 - 1.05) 0.158 0.99 (0.84 - 1.17) 0.898 
CVD-related variables (all baseline)              
Hypertension No 904.0 15300 5.91 (5.54 - 6.31)         
  Yes 379.0 5550 6.83 (6.17 - 7.55) 1.16 (1.03 - 1.30) 0.018 1.12 (0.98 - 1.28) 0.102 
On antihypertensives No 1200 19561 6.13 (5.80 - 6.49)         
  Yes 83.0 1289 6.44 (5.19 - 7.99) 1.05 (0.84 - 1.31) 0.668 0.80 (0.62 - 1.03) 0.088 
High Cholesterol No 666.0 11174 5.96 (5.52 - 6.43)         
  Yes 617.0 9677 6.38 (5.89 - 6.90) 1.07 (0.96 - 1.19) 0.228 0.97 (0.86 - 1.10) 0.650 
On lipid lowering drugs No 1219 19968 6.10 (5.77 - 6.46)         
  Yes 64.0 882.3 7.25 (5.68 - 9.27) 1.19 (0.92 - 1.53) 0.179 1.09 (0.84 - 1.43) 0.506 
Overweight No 962.0 16176 5.95 (5.58 - 6.33)         
  Yes 321.0 4674 6.87 (6.16 - 7.66) 1.15 (1.02 - 1.31) 0.025 1.10 (0.97 - 1.26) 0.147 
Diabetic No 1188 19693 6.03 (5.70 - 6.39)         
  Yes 95.0 1157 8.21 (6.72 - 10.04) 1.36 (1.10 - 1.68) 0.004 1.21 (0.98 - 1.51) 0.083 
Family History of CVD No 1149 18600 6.18 (5.83 - 6.55)         
  Yes 134.0 2250 5.96 (5.03 - 7.05) 0.96 (0.81 - 1.15) 0.689 0.97 (0.81 - 1.16) 0.743 
Prior CVD event No 1196 19986 5.98 (5.65 - 6.33)         
  Yes 87.0 863.8 10.07 (8.16 - 12.43) 1.68 (1.35 - 2.09) <.001 1.50 (1.19 - 1.89) <.001 
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Table 3c. Incidence Rates and Rate Ratios for reducing cholesterol 
 
   N PYFU Rate (95%CI) per 100 PYFU Univariable Multivariable 
     RR (95%CI) P-value RR (95%CI) P-value 
Total  277.0 7907 3.50 (3.11 - 3.94)     
Gender Female 26.0 690.7 3.76 (2.56 - 5.53)     
 Male 251.0 7216 3.48 (3.07 - 3.94) 0.92 (0.62 - 1.38) 0.701 1.33 (0.84 - 2.09) 0.221 
Age at baseline Per 10 years    0.85 (0.76 - 0.97) 0.013 1.02 (0.89 - 1.16) 0.792 
Year 2000-2001 14.0 344.7 4.06 (2.41 - 6.86)     
 2002-2003 36.0 773.0 4.66 (3.36 - 6.46) 1.15 (0.62 - 2.13) 0.664 1.28 (0.68 - 2.39) 0.444 
 2004-2005 20.0 1032 1.94 (1.25 - 3.00) 0.48 (0.24 - 0.94) 0.034 0.56 (0.27 - 1.15) 0.114 
 2006-2007 52.0 1244 4.18 (3.19 - 5.49) 1.03 (0.57 - 1.86) 0.924 1.21 (0.63 - 2.33) 0.565 
 2008-2009 48.0 1324 3.63 (2.73 - 4.81) 0.89 (0.49 - 1.62) 0.708 1.14 (0.58 - 2.23) 0.712 
 2010-2011 36.0 1281 2.81 (2.03 - 3.90) 0.69 (0.37 - 1.28) 0.242 0.88 (0.44 - 1.77) 0.717 
 2012-2014 71.0 1908 3.72 (2.95 - 4.70) 0.92 (0.52 - 1.62) 0.764 1.13 (0.58 - 2.21) 0.716 
Ethnicity White 250.0 7186 3.48 (3.07 - 3.94)     
 Non-white 27.0 720.9 3.75 (2.57 - 5.46) 1.08 (0.72 - 1.60) 0.716 1.00 (0.65 - 1.52) 0.982 
Mode of Infection MSM 138.0 4405 3.13 (2.65 - 3.70)     
 PWID 47.0 520.3 9.03 (6.79 - 12.02) 2.88 (2.07 - 4.01) <.001 1.67 (1.04 - 2.68) 0.032 
 Heterosexual 65.0 2258 2.88 (2.26 - 3.67) 0.92 (0.68 - 1.23) 0.574 0.74 (0.53 - 1.03) 0.074 
 Other/Unknown 27.0 724.1 3.73 (2.56 - 5.44) 1.19 (0.79 - 1.80) 0.408 0.95 (0.62 - 1.45) 0.807 
European Region South 80.0 2063 3.88 (3.11 - 4.83)     
 Central 102.0 2704 3.77 (3.11 - 4.58) 0.97 (0.73 - 1.30) 0.854 1.10 (0.80 - 1.53) 0.558 
 North 65.0 2140 3.04 (2.38 - 3.87) 0.78 (0.56 - 1.09) 0.143 1.12 (0.78 - 1.61) 0.533 
 East 29.0 903.9 3.21 (2.23 - 4.62) 0.83 (0.54 - 1.27) 0.382 1.22 (0.78 - 1.93) 0.383 
HIV-related variables        
CD4 group <200 36.0 435.4 8.27 (5.96 - 11.46)         
 200-350 52.0 1308 3.98 (3.03 - 5.22) 0.48 (0.31 - 0.74) <.001 0.56 (0.36 - 0.86) 0.009 
 350-500 71.0 1863 3.81 (3.02 - 4.81) 0.46 (0.31 - 0.69) <.001 0.58 (0.38 - 0.90) 0.015 
 >500 118.0 4300 2.74 (2.29 - 3.29) 0.33 (0.23 - 0.48) <.001 0.42 (0.27 - 0.65) <.001 
CD4 nadir <200 178.0 5137 3.47 (2.99 - 4.01)         
 >200 99.0 2762 3.58 (2.94 - 4.37) 1.03 (0.81 - 1.32) 0.787 1.05 (0.78 - 1.41) 0.747 
HIV RNA (cp/ml) <400 (suppressed) 222.0 7056 3.15 (2.76 - 3.59)         
 >400  55.0 845.3 6.51 (5.00 - 8.48) 2.07 (1.54 - 2.78) <.001 1.64 (1.16 - 2.33) 0.005 
Prior AIDS event No 174.0 5168 3.37 (2.90 - 3.91)         
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  Yes 103.0 2739 3.76 (3.10 - 4.56) 1.12 (0.88 - 1.43) 0.373 1.11 (0.85 - 1.44) 0.459 
Prior non-AIDS event (not CV) No 250.0 7386 3.38 (2.99 - 3.83)         
 Yes 27.0 520.7 5.18 (3.56 - 7.56) 1.53 (1.03 - 2.28) 0.035 1.50 (0.99 - 2.28) 0.056 
Cumulative cART exposure lt1 year 19.0 274.7 6.92 (4.41 - 10.84)         
 1-3 years 20.0 398.5 5.02 (3.24 - 7.78) 0.73 (0.39 - 1.36) 0.317 0.88 (0.46 - 1.69) 0.707 
 3-6 years 51.0 1399 3.64 (2.77 - 4.80) 0.53 (0.31 - 0.89) 0.017 0.62 (0.35 - 1.10) 0.103 
 >6 years 187.0 5834 3.21 (2.78 - 3.70) 0.46 (0.29 - 0.74) 0.001 0.60 (0.35 - 1.03) 0.062 
Hepatitis B No 244.0 7079 3.45 (3.04 - 3.91)         
 Yes 22.0 494.2 4.45 (2.93 - 6.76) 1.29 (0.83 - 2.00) 0.250 1.24 (0.79 - 1.95) 0.354 
 Unknown 11.0 334.0 3.29 (1.82 - 5.95) 0.96 (0.52 - 1.75) 0.882 0.77 (0.41 - 1.46) 0.425 
Hepatitis C No 175.0 5984 2.92 (2.52 - 3.39)         
 Yes 54.0 595.4 9.07 (6.95 - 11.84) 3.10 (2.29 - 4.21) <.001 1.48 (0.96 - 2.26) 0.075 
 Unknown 48.0 1328 3.62 (2.72 - 4.80) 1.24 (0.90 - 1.70) 0.193 1.00 (0.71 - 1.41) 0.997 
CVD-related variables (all baseline)        
Hypertension No 92.0 2800 3.29 (2.68 - 4.03)         
 Yes 185.0 5107 3.62 (3.14 - 4.18) 1.10 (0.86 - 1.42) 0.445 1.17 (0.87 - 1.58) 0.310 
On antihypertensives No 186.0 5665 3.28 (2.84 - 3.79)         
 Yes 91.0 2242 4.06 (3.30 - 4.98) 1.24 (0.96 - 1.59) 0.098 0.97 (0.71 - 1.32) 0.830 
High Cholesterol                
 Per 10       0.58 (0.52 - 0.63) <.001 0.62 (0.56 - 0.68) <.001 
On lipid lowering drugs No 238.0 6894 3.45 (3.04 - 3.92)         
 Yes 39.0 1013 3.85 (2.81 - 5.27) 1.12 (0.80 - 1.57) 0.526 0.92 (0.64 - 1.32) 0.640 
Current Smoker No 123.0 3624 3.39 (2.84 - 4.05)         
 Yes 152.0 4094 3.71 (3.17 - 4.35) 1.09 (0.86 - 1.39) 0.459 1.18 (0.91 - 1.54) 0.209 
 Ex 2.0 188.8 1.06 (0.27 - 4.24) 0.31 (0.08 - 1.26) 0.102 0.23 (0.06 - 0.97) 0.045 
Overweight No 171.0 4836 3.54 (3.04 - 4.11)         
 Yes 106.0 3071 3.45 (2.85 - 4.18) 0.98 (0.77 - 1.24) 0.846 1.02 (0.79 - 1.31) 0.892 
Diabetic No 142.0 5168 2.75 (2.33 - 3.24)         
 Yes 135.0 2739 4.93 (4.16 - 5.84) 1.79 (1.42 - 2.27) <.001 1.85 (1.42 - 2.40) <.001 
Family History of CVD No 238.0 7094 3.35 (2.95 - 3.81)         
 Yes 39.0 812.8 4.80 (3.51 - 6.57) 1.43 (1.02 - 2.01) 0.038 1.22 (0.86 - 1.74) 0.268 
Prior CVD event No 181.0 6350 2.85 (2.46 - 3.30)         
 Yes 96.0 1557 6.17 (5.05 - 7.53) 2.16 (1.69 - 2.77) <.001 1.98 (1.50 - 2.61) <.001 
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Figure 1. Baseline Factor Associated with a High CV risk (DAD) in Multivariable1 Logistic Regression Models 
1. The model was adjusted for all the factors listed in the Figure Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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OR (95% CI) 
Figure 2: Factors associated with the development of a high CV risk (DAD) in Multivariable1 Poisson Regression Model 
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Appendix: Tables and Figures 
Appendix Table 1: Formulas used to calculate the predicted risk estimates 
Risk Equation  Formulas and code1  
Framingham (5-year)   Equation and variables needed 
(Reproduced from Anderson et al, 1991) 
 
Framingham (1991) risk equation:  
 
 
 
 
 
 
 
β and θ constant values and variables needed:  
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Notes on equation set up:  
SBP is entered in mmHg, Total and HDL cholesterol in mg/dl 
SAS code 
(A Schultze, Oct. 2015) 
 
/*Variables used: 
framgend=gender (1=female, 0=male) 
rcurrage=age in years 
rbp=systolic blood pressure 
rhdl=hdl cholesterol 
rch=total cholesterol 
rdia=diabetes (1=yes, 0=No);  
lvh=ECG left ventricular hypertrophy 
*/ 
 
*total chol and hdl chol in mg/dl;  
if rch ne . then frch=rch*38.66976;  
if rhdl ne . then frhdl=rhdl*38.66976;  
 
if frch ge 0 & frhdl ge 0 then do; 
ratio=(frch/frhdl); 
 
*the prevalence of LVH, a rare condition, is presumed to be zero (Matthew Law, personal communication);  
lvh=0; 
 
theta0=0.6536; 
theta1=-0.2402; 
bet0=18.8144; 
female=-1.2146*framgend; 
lnage=(-1.8443*(log(rcurrage))); 
lnagefem=(0.3668*(log(rcurrage))*framgend; 
lnsbp=-1.4032*log(rbp); 
cig=-0.3899*risksmok; 
lntchdl=-0.5390*(log(ratio)); 
dbetes=-0.3036*rdia; 
dbetesfem=-0.1697*(rdia*framgend); 
ecg_lvh=-0.3362*lvh;  
 
mu=((bet0)+(female)+(lnage)+(lnagefem)+(lnsbp)+(cig)+(lntchdl)+(dbetes)+(dbetesfem)+(ecg_lvh)); 
 
sigma=exp(theta0+(theta1*mu)); 
 
u=(log(5)-mu{i}/sigma); 
 
riskfram=(1-exp(-exp(u))); 
 
Framingham (10-year)  Equation and variables needed 
(Reproduced from D’Agostino et al, 2008) 
 
Framingham (2008) risk equation:  
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β and θ constant values and variables needed:  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes on equation set up:  
The equation is set up separately for men and women.  
SBP is entered in mmHg, Total and HDL cholesterol in mg/dl.  
 
SAS code 
(A Schultze, Oct. 2015) 
/*Variables used: 
gender=gender(1=male, 2=female) 
rcurrage=age in years 
rbp=systolic blood pressure 
rhdl=hdl cholesterol 
rch=total cholesterol 
rdia=diabetes (1=yes, 0=No);  
lvh=ECG left ventricular hypertrophy 
rhyp=on antihypertensive drugs (1=yes) 
*/ 
 
*women;  
if gender=2 then do;  
 
wage=2.32888*(log(rcurrage)); 
wtch=1.20904*(log(frch)); 
whch=(-0.70833)*(log(frhdl)); 
if rhyp ne 1 then do; 
wsbpt=2.76157*(log(rbp)); 
end;  
if rhyp=1 then do;  
wsbpt=2.82263*(log(rbp)); 
end; 
wsm=0.52873*risksmok; 
wdb=0.69154*rdia; 
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wsum=wage+wtch+whch+wsbpt+wsm+wdb; 
 
up_frisk=1-(0.95012**(exp(wsum-26.1931)));  
 
end; 
 
*men;  
if gender=1 then do; 
 
mage=3.06117*(log(rcurrage)); 
mtch=1.12370*(log(frch)); 
mhch=(-0.93263)*(log(frhdl)); 
if rhyp ne 1 then do; 
msbpt=1.93303*(log(rbp)); 
end;  
if rhyp=1 then do;  
msbpt=1.99881*(log(rbp)); 
end; 
msm=0.65451*risksmok; 
mdb=0.57367*rdia; 
 
msum=mage+mtch+mhch+msbpt+msm+mdb; 
 
up_frisk=1-(0.88936**(exp(msum-23.9802)));  
D:A:D Risk Equation (5-year) 
 
Equation and variables needed 
(Reproduced from Friis-Moller et al, 2010) 
 
DAD risk equation:  
 
 
 
 
β constant values (in red) and variables needed:  
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Notes on equation set up:  
“Data in the DAD study are set up in monthly time units (0.085 years); the above equation therefore produces a monthly probability of developing CVD, CHD or MI. A reasonably 
good approximation for calculating the estimated probability over longer time periods, t, is to multiply ‘H′ by t years, and use indinavir + t/2 (if continuing on indinavir), lopinavir 
+ t/2 (if continuing lopinavir) and age + t/2 in the equation.”  
(Appendix, Friis-Moller et al, 2010) 
 
 
SAS code 
(A Schultze, Oct. 2015) 
 
/*Variables used: 
sumind=Cumulative exposure to indinavir  
sumlop=Cumulative exposure to lopinavir  
riskaba=On Abacavir (Yes=1, No=0) 
riskgend=Gender(Male=1, Female=0) 
rcurrage=Current age in years 
famhist=Family history of CVD (Yes=1, No=0) 
risksmok=Current smoker (Yes=1, No=0) 
texsmok=Ex smoker (Yes=1, No=0) 
rdia=Current Diabetes (Yes=1, No=0) 
rch=LDL Cholesterol  
rhdl=HDL Cholesterol  
rbp=Blood Pressure  
 
*/ 
 
*please note this is set up using absolute values, and minus signs added at the summation stage;  
beta0=10.970; 
 
if ind=1 then do; 
bet1a=0.041*(sumind+(5/2)); 
end;  
if ind=0 then do;  
bet1a=0.041*(sumind); 
end; 
 
if lop=1 then do; 
bet2a=0.077*(sumlop+(5/2)); 
end; 
if lop=0 then do;  
bet2a=0.077*(sumlop); 
end; 
 
bet3a=(0.489*riskaba); 
bet4a=0.530*riskgend; 
bet5a=0.348*(((rcurrage+(5/2))/5)); 
bet6a=0.361*famhist; 
bet7a=0.854*risksmok; 
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1. For simplicity, the code is displayed without arrays. In the analysis, the risk equations were calculated on a monthly time-scale.  
 
bet8a=0.238*texsmok; 
bet9a=0.652*rdia; 
bet10a=0.195*rch; 
bet11a=0.402*rhdl; 
bet12a=0.054*(rbp/10); 
sumrisk=((-beta0)+ bet1a + bet2a + bet3a + bet4a + bet5a + bet6a + bet7a + bet8a + bet9a + bet10a + (-bet11a) + bet12a); 
 
*this exponentiation stage is in accordance with the equation, but differs from the worked example in the Friis-Moller paper, due to an 
error (Matthew Law, pers. comm);  
riskex=(exp(sumrisk)); 
 
fiveyear=5*(riskex); 
 
risk=(1-exp(-fiveyear)); 
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Appendix Figure 1a-b: Distribution of the magnitude of blood pressure/cholesterol modification  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a. Distribution of the magnitude of systolic blood pressure reduction  (mm/Hg)1,2 
1. For example, an individual with a BP of 150/90 who lowered their BP to 130/80 would be classified as having modified their SBP 
with 20 mm/Hg.  
2. 131 individuals did not lower their systolic blood pressure but were still classified as having modified their blood pressure, as they 
met the EACS guidelines for indication for risk modification on the basis of their diastolic blood pressure values.  
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Figure 1b. Distribution of the magnitude of cholesterol reduction (mmol/Litre)1 
1. 48 individuals did not lower their cholesterol as compared to their baseline cholesterol, as indication for modification of cholesterol was based on CV risk and not on absolute cholesterol values (Table 1). This 
meant that some individuals could meet the definition for successful cholesterol modification without a relative decrease in their cholesterol levels. 
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